ArticleCureus2025
Efficacy of Intralesional Platelet-Rich Plasma in Patients With de Quervain's Tenosynovitis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background De Quervain's tenosynovitis is a disorder of the tendons of the first dorsal compartment of the wrist that causes pain and functional disability and may be refractory to conservative treatments. This research was done to determine the efficacy of intralesional platelet-rich plasma (PRP) in patients with de Quervain's tenosynovitis. Methodology This quasi-experimental study was performed at the Department of Orthopedic Surgery, King Edward Medical University/Mayo Hospital, Lahore, Pakistan, from September 2021 to October 2022. Patients of either gender, aged between 18 and 60 years, and presenting with de Quervain's tenosynovitis were analyzed. The patient received a PRP injection plus an oral nonsteroid anti-inflammatory drug (NSAID; naproxen 500 mg twice daily). The patient was evaluated three weeks after treatment for efficacy. Efficacy was labeled as a visual analog scale (VAS) pain score of < 3 after three weeks of intralesional PRP injection. Results In a total of 67 patients, 42 (62.7%) were male. The mean age was 44.26±6.48 years. The mean pre-treatment VAS score was 7.24±1.36. The mean post-treatment VAS score after 3 weeks of intralesional PRP injection was 2.14±0.63 (p<0.001). Patients with diabetes had higher post-treatment VAS scores (2.33±0.75) compared to those without (1.99±0.48), indicating a significant difference (p=0.025). Other characteristics, such as hypertension (p=0.334), family history of musculoskeletal disorders (p=0.704), duration of symptoms (0.346), hand dominance (p=0.516), and occupation (p=0.649), did not show significant differences in post-treatment VAS scores. Efficacy was achieved in 85.1% (n=57) of patients. Non-efficacy was significantly associated with diabetes mellitus (80% of non-responders vs. 36.8% of responders, p=0.011). Other factors, such as gender (p=0.289), age (p=0.279), BMI (p=0.258), residence (p=0.933), smoking history (p=0.358), hypertension (p=0.808), family history of musculoskeletal disorders (p=0.553), symptom duration (p=0.983), hand dominance (p=0.096), or occupation (p=0.935), were not significantly associated with treatment efficacy. Conclusion Intralesional PRP injections provide effective pain relief in the majority of patients with de Quervain's tenosynovitis. While the treatment appears effective across most patient subgroups, diabetes mellitus significantly reduces the likelihood of success, indicating the need for personalized treatment approaches in such cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.